NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd. has regained full compliance with Nasdaq’s listing requirements, a move that highlights the company’s efforts to strengthen its financial position through capital raising and a reverse share split. This development is a promising signal for investors interested in the biopharmaceutical sector, as NLS continues to advance its innovative therapies for rare central nervous system disorders.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
